Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study

被引：0
|
作者：
Shi, Y-K. [1 ]
Gao, L. [2 ]
Tian, Y. [3 ]
Chen, J. [4 ]
Wang, J. [3 ]
Bai, C. [5 ]
Li, X. [6 ]
Su, H. [7 ]
Liu, Z. [8 ]
机构：
[1] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Gansu Prov Canc Hosp, Dept Radiotherapy, Lanzhou, Peoples R China
[3] Gansu Prov Canc Hosp, Head & Neck Serv, Lanzhou, Peoples R China
[4] Cent South Univ, Xiangya Med Sch, Hunan Canc Hosp, Dept Thorac Surg 1, Changsha, Peoples R China
[5] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[7] Fourth Mil Med Univ, Tangdu Hosp, Oncol Dept, Xian, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Oncol, Dept Head & Neck Serv, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908P
引用
收藏
页码：S806 / S806
页数：1
相关论文
共 50 条
  • [21] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Patricia A. Tang
    Lillian L. Siu
    Eric X. Chen
    Sebastien J. Hotte
    Stephen Chia
    James K. Schwarz
    Gregory R. Pond
    Caitlin Johnson
    A. Dimitrios Colevas
    Timothy W. Synold
    Lakshmi S. Vasist
    Eric Winquist
    Investigational New Drugs, 2008, 26 : 257 - 264
  • [22] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [23] Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Fury, Matthew G.
    Baxi, Shrujal
    Shen, Ronglai
    Kelly, Katherine W.
    Lipson, Brynna L.
    Carlson, Diane
    Stambuk, Hilda
    Haque, Sofia
    Pfister, David G.
    ANTICANCER RESEARCH, 2011, 31 (01) : 249 - 253
  • [24] Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV plus R/M HNSCC)
    Aggarwal, C.
    Saba, N. F.
    Algazi, A. P.
    Sukari, A.
    Seiwert, T.
    Haigentz, M.
    Porosnicu, M.
    Bonomi, M.
    Boyer, J.
    Durham, N.
    Kumar, R.
    Laubscher, K.
    Gong, M.
    Ceaicovscaia, N.
    Hernandez, A. Gasco
    ANNALS OF ONCOLOGY, 2020, 31 : S661 - S662
  • [25] Phase II trial evaluating axitinib for patients with uaresectable, recurrent, or metastatic (R/M) bead and neck squamous cell carcinoma (HNSCC)
    Sacco, Assuntina Gesualda
    Zhao, Lill
    Carey, Thomas E.
    Dobrosotskaya, Irina Y.
    McHugh, Jonathan B.
    Chepeha, Douglas Brian
    Bradford, Carol Roasler
    Wolf, Gregory T.
    Prince, Mark E.
    Moyer, Jeffrey
    McKean, Erin Lynn
    McLean, Scott A.
    Malloy, Kelly M.
    Spector, Matthew E.
    Hogikyan, Norman D.
    Urba, Susan
    Ward, Brent
    Worden, Francis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Chung, Christine H.
    Saba, Nabil F.
    Steuer, Conor Ernst
    Li, Jiannong
    Bhateja, Priyanka
    Johnson, Matthew
    Masannat, Jude
    Poole, Maria
    Hoening, Dirk
    Song, Feifei
    Hernandez-Prera, Juan C.
    Molina, Helen
    Wenig, Bruce
    Farinhas, Joaquim
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Schell, Michael J.
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Dunn, L. A.
    Fury, M. G.
    Xiao, H.
    Baxi, S. S.
    Sherman, E. J.
    Korte, S.
    Pfister, C.
    Haque, S.
    Katabi, N.
    Ho, A. L.
    Pfister, D. G.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2533 - 2538
  • [28] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
    Guo, Ye
    Li, Zhendong
    Chen, Wantao
    Fang, Meiyu
    Liu, Zhigang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Lee, Ji Hyun
    Heo, Seong Gu
    Ahn, Beung-Chul
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    Kim, Hye Ryun
    CANCER MEDICINE, 2021, 10 (20): : 7012 - 7020
12345